About VantAI:
VantAI is building a computational pipeline combining state-of-the-art physics-based modeling and machine learning to revolutionize drug discovery and development. Working together with some of the world’s leading biopharmaceutical companies, we design, test and optimize novel therapies to treat some of the world’s most difficult diseases.
Key Responsibilities:
- Design and implement roadmap to set up a new experimental hub for VantAI
- Manage day-to-day operations with the internal team to achieve roadmap milestones
- Manage relationships with external collaborators and stakeholders
Requirements
- Strategy & Operations experience, ideally in a high-pressure multi-stakeholder environment (e.g., consulting, M&A, private equity, etc.)
- Hands-on team management experience
- Master/undergrad degree in biology, chemistry, or similar
Preferred Requirements
- PhD in proteomics or area related to protein interactions
- Degree in statistics, computer science, AI/ML, or similar
- Experience working with mass spectrometry
New York, New York
Salary: $130,000 - $160,000
This band is a reflection of the job description as written. Looking for a higher salary? Apply anyway! We are happy to speak to more experienced candidates who may require a higher salary and discuss that experience in our first touchpoint.
Top Skills
What We Do
VantAI pairs bleeding-edge machine learning techniques with deep systems biology expertise to build computational models that uncover hidden relationships between molecules, targets, and diseases. These models power a best-in-class solution that identifies and generates new molecular entities for targets of interest, repurposes existing molecules at any stage of development, uncovers accurate ADME and toxicological insights, and predicts adverse events likely to influence trial success from deep analysis of systems-based pharmacogenomics. VantAI's in silico platform specializes in modelling complex protein-protein interactions, powering the discovery of biologics and protein degraders in addition to small-molecule drugs. It has helped leading biopharma partners launch new development programs--or revitalize old ones--at a fraction of the time and cost of traditional methods. For more information, please visit http://www.vant.ai.
